statement
Pharmaceutical and bio stocks were strong on rotation, with Celltrion up 7.3%, Hanmi Pharm up 9.8%, SK Biopharmaceuticals up 11.4% and Samsung Epis Holdings up 14.0%.
A statement by FICC리서치부 전략/시황: 이경민. Statements are as reported by the cited publishers — not verified by DecisionGateway.
반면, 제약/바이오 업종 강세. 셀트리온(+7.3%), 한미약품(+9.8%), SK바이오팜(+11.4%), 삼성에피스홀딩스(+14.0%) 등 순환매 양상
Related claims
Bargain hunting flowed in, with oversold stocks such as semiconductors, secondary batteries, power equipment and aviation leading the rebound.퀀틴전시 플랜 · statementSun Pharma emerged among the top gainers.moneycontrolcom · statementBuy the KOSPI in tranches below 5,600p, with semiconductors, shipbuilding and biotech as core holdings.대신증권 이경민 · commitmentSemiconductor stocks extended losses, with Samsung Electronics down 8.0%, SK Hynix down 9.7%, Hanmi Semiconductor down 9.4% and SK Square down 10.8%.FICC리서치부 전략/시황: 이경민 · statementIn the previous day's US market, bargain hunting flowed into the semiconductor sector, which had fallen excessively, with Micron, SanDisk, AMD and Broadcom surging.FICC리서치부 전략/시황: 이경민 · statementHanAll Biopharma is forecast to post 2027 revenue of 177.3 billion KRW, operating profit of 10.6 billion KRW, and an operating margin of 6.0%.report author · prediction